JO3676B1 - مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها - Google Patents

مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها

Info

Publication number
JO3676B1
JO3676B1 JOP/2010/0261A JOP20100261A JO3676B1 JO 3676 B1 JO3676 B1 JO 3676B1 JO P20100261 A JOP20100261 A JO P20100261A JO 3676 B1 JO3676 B1 JO 3676B1
Authority
JO
Jordan
Prior art keywords
methods relating
pharmaceutical compositions
modified fucans
fucans
modified
Prior art date
Application number
JOP/2010/0261A
Other languages
English (en)
Inventor
Christopher Michael Kevin Springate
Original Assignee
Arc Medical Devices Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arc Medical Devices Inc filed Critical Arc Medical Devices Inc
Application granted granted Critical
Publication of JO3676B1 publication Critical patent/JO3676B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات وطرق تتعلق بعوامل الفيوكان المفيدة في علاج الالتصاقات الليفية أو الأمراض الأخرى والوقاية منها وتثبيطها...الخ.
JOP/2010/0261A 2009-07-27 2010-07-25 مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها JO3676B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22892909P 2009-07-27 2009-07-27

Publications (1)

Publication Number Publication Date
JO3676B1 true JO3676B1 (ar) 2020-08-27

Family

ID=43497856

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0261A JO3676B1 (ar) 2009-07-27 2010-07-25 مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها

Country Status (19)

Country Link
US (6) US8466125B2 (ar)
EP (2) EP3300737A1 (ar)
JP (5) JP2013500274A (ar)
KR (1) KR20120083297A (ar)
CN (2) CN102665733B (ar)
AR (1) AR078082A1 (ar)
AU (4) AU2010278640A1 (ar)
BR (1) BR112012008072A2 (ar)
CA (2) CA2769147A1 (ar)
CL (1) CL2012000215A1 (ar)
EA (1) EA201270186A1 (ar)
IN (1) IN2012DN01314A (ar)
JO (1) JO3676B1 (ar)
MX (1) MX2012001212A (ar)
MY (1) MY168759A (ar)
SG (3) SG177741A1 (ar)
TW (2) TWI569801B (ar)
WO (1) WO2011011881A1 (ar)
ZA (1) ZA201200999B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809303B1 (en) * 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
JP2013521300A (ja) * 2010-03-03 2013-06-10 ネオキュティス エスアー 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法
FR2984126B1 (fr) * 2011-12-20 2014-08-22 Oreal Polysaccharides sulfates agent antipelliculaire
CN107580497A (zh) * 2015-02-16 2018-01-12 克桑蒂亚尔 用于预防或治疗皮肤病症的组合物
CN105663154B (zh) * 2016-01-18 2020-06-30 首都医科大学 褐藻多糖硫酸酯在制备预防和/或治疗下肢外周动脉血管病的产品中的应用
US20180056087A1 (en) * 2016-08-26 2018-03-01 Adolfo Ribeiro Wearable Micro-LED Healing Bandage
CN106943619A (zh) * 2017-03-17 2017-07-14 清华大学 一种液体伤口敷料及其制备方法
US11642368B2 (en) 2018-07-27 2023-05-09 ARC Medical Inc. Highly purified and/or modified fucan compositions for the treatment of fibrous adhesions
CN115260328A (zh) * 2022-08-14 2022-11-01 湘潭大学 一种改性岩藻多糖化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IT1288713B1 (it) * 1996-12-18 1998-09-23 Crinos Industria Farmaco Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
FR2772618B1 (fr) * 1997-12-18 2000-02-18 Ifremer Utilisation de fucane comme regulateur de la reconstruction des tissus conjonctifs
KR100675541B1 (ko) * 1999-08-20 2007-01-29 다카라 바이오 가부시키가이샤 치료제
US6812220B2 (en) * 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
NO320671B1 (no) * 2001-11-30 2006-01-16 Fmc Biopolymer As Fremgangsmate for a stimulere vektokning i fisk.
AU2004243513A1 (en) * 2003-05-30 2004-12-09 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
CN1829501A (zh) * 2003-05-30 2006-09-06 Arc药品有限公司 涉及使用多种药物抑制纤维粘连的药用组合物和方法
EP1809303B1 (en) 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
US8426381B2 (en) * 2005-09-09 2013-04-23 Lucas Meyer Cosmetics Canada Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
CN1935154A (zh) * 2006-09-04 2007-03-28 北京世纪博康医药科技有限公司 褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途
EP2121767B1 (en) * 2007-02-23 2014-04-09 Baxter International Inc. Process methods for fucoidan purification from seaweed extracts
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها

Also Published As

Publication number Publication date
EP2459200A4 (en) 2013-02-27
JP2017206542A (ja) 2017-11-24
JP2021020907A (ja) 2021-02-18
EP3300737A1 (en) 2018-04-04
SG10201808960VA (en) 2018-11-29
US20180051097A1 (en) 2018-02-22
AU2018203461A1 (en) 2018-06-07
JP2019142896A (ja) 2019-08-29
MX2012001212A (es) 2012-07-17
TW201105342A (en) 2011-02-16
US20110021457A1 (en) 2011-01-27
AU2016219615A1 (en) 2016-09-15
AU2019268096A1 (en) 2019-12-12
KR20120083297A (ko) 2012-07-25
JP2016128491A (ja) 2016-07-14
BR112012008072A2 (pt) 2016-03-01
US20180230240A1 (en) 2018-08-16
SG177741A1 (en) 2012-02-28
CA3046665A1 (en) 2011-02-03
CL2012000215A1 (es) 2012-07-13
TW201532607A (zh) 2015-09-01
US20200115472A1 (en) 2020-04-16
US8466125B2 (en) 2013-06-18
AU2010278640A1 (en) 2012-03-15
EP2459200A1 (en) 2012-06-06
ZA201200999B (en) 2013-05-29
AR078082A1 (es) 2011-10-12
WO2011011881A1 (en) 2011-02-03
CN106176798A (zh) 2016-12-07
JP2013500274A (ja) 2013-01-07
CA2769147A1 (en) 2011-02-03
TWI569801B (zh) 2017-02-11
CN102665733B (zh) 2016-08-10
EA201270186A1 (ru) 2012-09-28
CA3046665C (en) 2021-03-23
MY168759A (en) 2018-12-04
IN2012DN01314A (ar) 2015-06-05
TWI491396B (zh) 2015-07-11
CN102665733A (zh) 2012-09-12
US20140274942A1 (en) 2014-09-18
US20140128340A1 (en) 2014-05-08
SG10201401436VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
MX336381B (es) Boronatos como inhibidores de arginasa.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IN2012DN00971A (ar)
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
IN2012DN02805A (ar)
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
EP2477985A4 (en) CANCER TREATMENT
EP2493464A4 (en) METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS
MA33803B1 (ar) مثبط برومودومين البنزوديازيبين
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
IN2012DN02471A (ar)
IN2012DN01233A (ar)
IN2012DN00624A (ar)
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MY161495A (en) Virus like particle compositions and methods of use
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors